Article
Comparison of HPV genotyping assays and Hybrid Capture 2 for detection of high-risk HPV in cervical specimens.
Annals of clinical and laboratory science - 1 Jan 2011
Um Tae Hyun, Lee Eun Hee, Chi Hyun-Sook, Kim Jong-Won, Hong Young-Joon, Cha Young Joo
Abstract excerpt
High-risk types of human papillomavirus (HR-HPV) are among the primary causes of cervical cancers. Hybrid Capture 2 (HC-II) (Digene, Gaithersburg, MD), which detects 13 HR-HPVs as a group, is the only HPV assay approved to date by the United States Food and Drug Administration. In Korea, several HPV genotyping assays are commercially available, including HPV RFMP (GeneMatrix Co., Seoul), HPVDNACHIP (Biomedlab...
Topics
- Biological Assay
- Cervix Uteri
- DNA, Viral
- Female
- Genotype
- Humans
- Papillomaviridae
- Reagent Kits, Diagnostic
- Risk Factors
- Vaginal Smears